KUMAMOTO University

R

研究実績RESEARCH ACHIEVEMENTS

  1. Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM.

    Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.

    Blood Advances.2019 Apr 9;3(7):995-1002. doi: 10.1182/bloodadvances.2018028456.  PMID: 30940634

     

  2. Bangham CRM, Miura M, Kulkarni A, and Matsuoka M.

    Regulation of Latency in the Human T Cell Leukemia Virus, HTLV-1.

    Annu Rev Virol 6:365-385, 2019.

    https://pubmed.ncbi.nlm.nih.gov/31283437/

  3. Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

    Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

    Nat Commun.2019 Apr 10;10(1):1653. doi: 10.1038/s41467-019-09710-z. PMID: 33197296

  4. Alam MM, Kuwata T, Tanaka K, Alam M, Takahama S, Shimura K, Matsuoka M, Fukuda N, Morioka H, Tamamura H, and Matsushita S.

    Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors.

    Biochem Biophys Rep 20:100687,

    https://pubmed.ncbi.nlm.nih.gov/31650039/

     

  5. Matsumura T, Nakamura-Ishizu A, Takaoka K, Maki H, Muddineni SSNA, Wang CQ, Suzushima H, Kawakita M, Asou N, Matsuoka M, Kurokawa M, Osato M, and Suda T.

    TUBB1 dysfunction in inherited thrombocytopenia causes genome instability.

     Br J Haematol. 2019 Jun;185(5):888-902. doi: 10.1111/bjh.15835. Epub 2019 Mar 10.

     

  6. Oda S, Nakaura T, Utsunomiya D, Hirakawa K, Takashio S, Izumiya Y, Tsujita K, Kawano Y, Okuno Y, Hata H, Matsuoka M, Yamashita T, Ueda M, Ando Y, Yamashita Y.

    Clinical potential of dual-energy cardiac CT in cardiac amyloidosis.

     Amyloid.2019;26(sup1):91-92. doi: 10.1080/13506129.2019.1582021. PMID: 31343298

  7. Murata S, Mushino T, Hosoi H, Kuriyama K, Nishikawa A, Nagakura S, Horikawa K, Yonemura Y, Nakakuma H, Sonoki T, Hanaoka N.

    Soluble NKG2D ligands are potential biomarkers and sentinels of  immune-mediated bone marrow injury in bone marrow failure syndromes.

    Acta Haematol.2020;143(1):33-39.  doi: 10.1159/000500657. Epub 2019 Jun 19. PMID: 31216534

  8. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Choi I, Otsuka E, Henzan H, Kato K, Nakachi S, Yamamoto H, Fukuda T.

    Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.

    Bone Marrow Transplant. 2019 Jan;54(1):134-137. doi: 10.1038/s41409-018-0248-8. Epub 2018 Jun 13. PMID: 29899570.

    https://pubmed.ncbi.nlm.nih.gov/29899570/

     

  9. Amano M, Salcedo-Gómez PM, Yedidi RS, Zhao R, Hayashi H, Hasegawa K, Nakamura T, Martyr CD, Ghosh AK, Mitsuya H.

    Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

    Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00466-19. doi: 10.1128/AAC.00466-19. PMID: 31061155; PMCID: PMC6591644.

    https://pubmed.ncbi.nlm.nih.gov/31061155/

     

  10. Maeda M, Muraki Y, Kosaka T, Yamada T, Aoki Y, Kaku M, Kawaguchi T, Seki M, Tanabe Y, Fujita N, Morita K, Yanagihara K, Yoshida K, Niki Y.

    The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy.

    J Infect Chemother. 2019 Feb;25(2):83-88. doi: 10.1016/j.jiac.2018.11.001. Epub 2018 Nov 22. PMID: 30473181.

    https://pubmed.ncbi.nlm.nih.gov/30473181/

     

  11. Amano M, Bulut H, Tamiya S, Nakamura T, Koh Y, Mitsuya H.

    Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition.

    Sci Rep. 2019 Jul 8;9(1):9806. doi: 10.1038/s41598-019-46082-2. PMID: 31285456; PMCID: PMC6614453.

    https://pubmed.ncbi.nlm.nih.gov/31285456/

     

  12. Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, Takaki A, Iwanaga K, Nishimura N, Fuji S, Fukuda T, Nosaka K, Matsuoka M.

    Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.

    Bone Marrow Transplant. 2019 Feb;54(2):338-342. doi: 10.1038/s41409-018-0291-5. Epub 2018 Aug 16. PMID: 30116017.

    https://pubmed.ncbi.nlm.nih.gov/30116017/

     

  13. Takamatsu Y, Aoki M, Bulut H, Das D, Amano M, Sheri VR, Kovari LC, Hayashi H, Delino NS, Ghosh AK, Mitsuya H.

    Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

    Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00372-19. doi: 10.1128/AAC.00372-19. PMID: 31085520; PMCID: PMC6658756.

    https://pubmed.ncbi.nlm.nih.gov/31085520/

     

  14. Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, Kato K, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R.

    Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.

    Br J Haematol. 2019 Feb;184(3):479-483. doi: 10.1111/bjh.15123. Epub 2018 Feb 7. PMID: 29411857.

    https://pubmed.ncbi.nlm.nih.gov/29411857/

     

  15. Ma G, Yasunaga JI, Ohshima K, Matsumoto T, and Matsuoka M.

    Pentosan polysulfate demonstrates anti-HTLV-1 activities in vitro and in vivo.

    J Virol 93:e00413-19, 2019.

    https://pubmed.ncbi.nlm.nih.gov/31167921/

     

  16. Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, Takaki A, Iwanaga K, Nishimura N, Fuji S, Fukuda T, Nosaka K, Matsuoka M.

    Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.

    Bone Marrow Transplant. 2019 Feb;54(2):338-342. doi: 10.1038/s41409-018-0291-5. Epub 2018 Aug 16. PMID: 30116017.

    https://pubmed.ncbi.nlm.nih.gov/30116017/

     

  17. Iriyama N, Tokuhira M, Sato E, Sugimoto K J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

    Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

    Hematol Oncol . 2019 Aug;37(3):323-325.doi: 10.1002/hon.2617. Epub 2019 Apr 26. PMID: 30950076

  18. Ito R, Inamoto Y, Inoue Y, Ito A, Tanaka T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Yamashita T, Fukuda T.

    Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients.

    Biol Blood Marrow Transplant. 2019 Feb;25(2):293-300. doi: 10.1016/j.bbmt.2018.09.014. Epub 2018 Sep 19. PMID: 30244104.

    https://pubmed.ncbi.nlm.nih.gov/30244104/

     

  19. Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno Y, Nosaka K, Matsuoka M, and Suzu S.

    Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.

    Clin Transl Immunology.2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019. PMID: 31417675

    https://pubmed.ncbi.nlm.nih.gov/31417675/

     

  20. Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T.

    New Target investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

    Int J Hematol .2019 Apr;109(4):426-439.  doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb14.PMID: 30762219

    https://pubmed.ncbi.nlm.nih.gov/30762219/

     

  21. Onitsuka K, Tokuda R, Kuwata-Higashi N, Kumamoto H, Aoki M, Amano M, Kohgo S, Das D, Haraguchi K, Mitsuya H, Imoto S.

    Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

    Nucleosides Nucleotides Nucleic Acids. 2019 Sep 12;1-12. doi: 10.1080/15257770.2019.1664749. [Epub ahead of print]. PMID: 31514570.

    https://pubmed.ncbi.nlm.nih.gov/31514570/

  22. Tagaya Y, Matsuoka M, Gallo R.

    40 years of the human T-cell leukemia virus: past, present, and future.

    F1000Res. 2019 Feb 28;8:F1000 Faculty Rev-228. doi: 10.12688/f1000research.17479.1. PMID: 30854194; PMCID: PMC6396841.

    https://pubmed.ncbi.nlm.nih.gov/30854194/

     

  23. Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.

    Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.

    Cancer Sci. 2019 Oct;110(10):3275-3287. doi: 10.1111/cas.14154. Epub 2019 Aug 14. PMID: 31368616; PMCID: PMC6778635.

    https://pubmed.ncbi.nlm.nih.gov/31368616/

     

  24. Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, Farid R, Imaizumi Y, Choi I, Ishida T, Ishitsuka K, Fukushima T, Uchimaru K, Takaori-Kondo A, Tokura Y, Utsunomiya A, Matsuoka M, Tsukasaki K, Watanabe T.

    Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

    J Clin Oncol. 2019 Mar 10;37(8):677-687. doi: 10.1200/JCO.18.00501. Epub 2019 Jan 18. PMID: 30657736; PMCID: PMC6494249.

    https://pubmed.ncbi.nlm.nih.gov/30657736/

     

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.